Ernexa Therapeutics Inc. booked $582.0k in FY2024 revenue, growing 756% year over year — faster than 96% of Healthcare companies we track, at a -2419.9% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.